DocumentsDate added
Research article:-
Maryam Rafieirad*, Saeed Valipour Chehardacheric & Zahra Zangeneh Nezhad.
Affiliation:-
Department of Biology, Faculty of Sciences, Islamic Azad University, Izeh Branch, Khouzestan, Iran.
Author contributions: - All authors contributed equally to this paper.
Abstract:
Background: Diabetes complications are caused by production of free radicals. Gallic acid (GA) has an antioxidant property and activity against free radicals. The aim of this study was to determine possible protective effect of GA on lipid profile in diabetic rats. Materials and Method: The experimental study was carried out on 35 male rats. Male rats were randomly divided to five groups; of control, untreated diabetic and diabetic groups treated with GA (10, ¬50, ¬100 mgkg/ orally, 14 days). Diabetes was induced by streptozotocin (STZ 60 Mg/kg) injection. After 2 weeks, serum levels of glucose and lipid profiles of all the groups were analyzed. Results: Results of this study showed that diabetes led to a significant increase at blood glucose (p<0/001), triglycerides (p<0/001), cholesterol (p<0/001), VLDL (p<0/001) and LDL (p<0/05) and a significant reduction at HDL (p<0/001) levels. Oral administration of GA to diabetic rats for two weeks at doses of 10, 50 and 100 mg/kg, reduced blood glucose, triglycerides and cholesterol levels, but resulted in subtle reductions in cholesterol and triglycerides in diabetic rats treated with 100 mg/kg GA; the difference was significant for other groups. Conclusion: Results of this study showed that GA had a beneficial effect on serum lipid profile in diabetic rats and could possibly be used for treating diabetes and reducing complications of this disease.
Key Words: Gallic acid; lipid profile; diabetic rats.
References
1.Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008; 51:216-26.
2.Kaneto H, Matsuoka TA, Nakatani Y, et al. Oxidative stress, ER stress, and the JNK pathway in type 2 diabetes. J Mol Med (Berl) 2005; 83:429-39.
3.Xiao CY, Chen M, Zsengeller Z, Szabo C. Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor. J Pharmacol Exp Ther 2004; 310:498-504.
4.Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008; 31:811-22.
5.American Diabetes Association (ADA),Standards of medical care in diabetes--2007. Diabetes Care 2007; 30 Suppl 1:S4-S41
6.Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res;107:1058-70.
7.Perron NR, Brumaghim JL. A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. Cell Biochem Biophys 2009;53:75-100.
8.Kim SH, Jun CD, Suk K, et al. Gallic acid inhibits histamine release and pro-inflammatory cytokine production in mast cells. Toxicol Sci 2006;91:123-31.
9.Kaur M, Velmurugan B, Rajamanickam S, Agarwal R, Agarwal C. Gallic acid, an active constituent of grape seed extract, exhibits anti-proliferative, pro-apoptotic and anti-tumorigenic effects against prostate carcinoma xenograft growth in nude mice. Pharm Res 2009;26:2133-40.
10.Sabu MC, Smitha K, Kuttan R. Anti-diabetic activity of green tea polyphenols and their role in reducing oxidative stress in experimental diabetes. J Ethnopharmacol 2002; 83:109-116.
11.Picerno P, Mencherini T, Lauro MR, Barbato F, Aquino R. Phenolic constituents and antioxidant properties of Xanthosoma violaceum leaves. J Agric Food Chem 2003; 51:6423-8.
12.Hosseini E, Karimzadeh K, Vessal M, Rafieirad M. Effects of a hydroalcoholic extract of walnut male flowers on streptozocin diabetic rats. HealthMED Journal 2012; 6 12:4253-7.
13.Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998;81:26B-31B.
14.Porte D, Jr., Kahn SE. Mechanisms for hyperglycemia in type II diabetes mellitus: therapeutic implications for sulfonylurea treatment--an update. Am J Med 1991;90:8S-14S.
15.Ahmed D, Sharma M, Pillai KK. The effects of triple vs. dual and monotherapy with rosiglitazone, glimepiride, and atorvastatin on lipid profile and glycemic control in type 2 diabetes mellitus rats. Fundam Clin Pharmacol; 26:621-31.
16.Lowe LP, Liu K, Greenland P, et al. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997; 20:163-9.
17.Sarkaki A, Rafieirad M, Hossini E, Farbood Y, Mansouri MT, Motamedi F.Cognitive deficiency induced by cerebral hypoperfusion/ischemia improves by exercise and grape seed extract HealthMED Journal 2012; 6:1097-1105.
18.Mansouri MT, Farbood Y, Jafar Sameri M, Sarkaki A, Naghizadeh B, Rafieirad M (2012), Neuroprotective effects of oral gallic acid against oxidative stress induced by 6-hydroxydopamine in rats. Food Chemistry 2012; 138, 2–3:1028-33.
19.Jiang F, Dusting GJ. Natural phenolic compounds as cardiovascular therapeutics: potential role of their antiinflammatory effects. Curr Vasc Pharmacol 2003;1:135-56.
20.Bose KS, Agrawal BK. Effect of lycopene from tomatoes (cooked) on plasma antioxidant enzymes, lipid peroxidation rate and lipid profile in grade-I hypertension. Ann Nutr Metab 2007; 51:477-81.
21.Kaliora AC, Dedoussis GV. Natural antioxidant compounds in risk factors for CVD. Pharmacol Res 2007;56:99-109.
22.Garjani A, Fathiazad F, Zakheri A, et al. The effect of total extract of Securigera securidaca L. seeds on serum lipid profiles, antioxidant status, and vascular function in hypercholesterolemic rats. J Ethnopharmacol 2009; 126:525-32.
23.Jayasooriya AP, Sakono M, Yukizaki C, et al. Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. J Ethnopharmacol 2000; 72:331-6.
24.Harris CS, Beaulieu LP, Fraser MH, et al. Inhibition of advanced glycation end product formation by medicinal plant extracts correlates with phenolic metabolites and antioxidant activity. Planta Med; 77:196-204
25.Kim YJ. Antimelanogenic and antioxidant properties of gallic acid. Biol Pharm Bull 2007; 30:1052-5.
Article citation:-
Rafieirad M , Chehardacheric S V, & Nezhad N N. Hypolipidemic effects of gallic acid in diabetic rats. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(33): 1309-1312.
Copyright © 2013 Rafieirad M , Chehardacheric S V, & Nezhad N N. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Review article:-
Swaminathan.S1*, Revathy.K2, Rajeswari.S 3 & Emila.S 4
Affiliation:-
1Chief of Biochemistry, 2Technical Supervisor, 3Lab Technologist, 4Lab Technologist, SRM Medical College Hospital and Research Centre, Kattankulathur, Kancheepuram District – 603 203, Tamil Nadu, India.
Abstract:
The two most important macrometals which play a major significant role in restoring good health are calcium and magnesium both of which are linked to the non-metal phosphorus. In many biochemical reactions both calcium and magnesium act together. Calcium plays a major role in arresting oxidative stress and free radical accumulation both of which are linked to cancer. This review article brings about all the works done during the last 4 decades on calcium in human health and disease, the deficiency manifestations, recommendations for supplementation and highlighting various diseases that are associated with calcium deficiency. The contents of this paper will certainly serve as an eye opener for future research on calcium in the diagnosis of various disorders.
Key Words: Calcium, CHD, CAC, CVD, IHD, ESRD, RBC, RT, CAPD, Vitamin D, 5 – HT, IBD, CKD, RDA, PTH, RT, Hypercalcemia, Hypocalcemia.
1.Josette Guillemant, Huyen-Tran Le, Chantal Accarie, Sophie Tézenas du Montcel, Anne-Marie Delabroise, Maurice J Arnaud, and Serge Guillemant. Mineral water as a source of dietary calcium: acute effects on parathyroid function and bone resorption in young men. Am J Clin Nutr 2000; 71; 4: 999-1002.
2.Marc T. Goodman, Anna H. Wu, Ko-Hui Tung, Katharine McDuffie, Laurence N. Kolonel, Abraham M. Y. Nomura, Keith Terada, Lynne R. Wilkens, Suzanne Murphy and Jean H. Hankin. Association of Dairy Products, Lactose, and Calcium with the Risk of Ovarian Cancer. Am J Epidemiol 2002;156:148–57.
3. David A Bushinsky, Rebeca D Monk. Calcium. Lancet 2002; 359; 9302:266.
4.Alec Coppen, D. Frizel and V. Marks. Plasma Magnesium and Calcium in Depression. The British Journal of Psychiatry (1969)115: 1375 -1377.
5.D Katsoff and J H Check. A challenge to the concept that the use of calcium channel blockers causes reversible male infertility.Hum.Reprod. 1997;12 (7):1480-2.
6. Storstein L, Larsen A, Midtbø K, Saevareid L. Pharmacokinetics of calcium blockers in patients with renal insufficiency and in geriatric patients. Acta Medica Scandinavica. Supplementum 1984; 681:25-30.
7. Joseph Levy, M. James R. Gavin, James R. Sowers. Diabetes mellitus: A disease of abnormal cellular calcium metabolism? The American Journal of Medicine 1994; 96; 3:260–73.
8.Philip Raskin, Muriel R. M. Stevenson, Donald E. Barilla, Charles Y. C. Pak. The Hypercalciuria of Diabetes Mellitus. Clinical Endocrinology 1978; 9; 4: 329–35.
9. Ravi Dhingra, Lisa M. Sullivan, Caroline S. Fox, Thomas J. Wang, Ralph B. D’Agostino, J. Michael Gaziano, Ramachandran S. Vasan. Arch Intern Med. 2007; 167(9):87-985.
10.David A McCarron, Molly E Reusser. Are low intakes of calcium and potassium important causes of cardiovascular disease? American Journal of Hypertension 2001; 14; 6(1); S206–12.
11.P.C. Elwood, P.M. Sweetnam, W.H. Beasley, D. Jones, R. France. Magnesium and Calcium in the Myocardium: Cause of Death and Area Differences. The Lancet (1980) Vol 316;8197:720–722.
12. William H Frishman, M. Dror Michaelson. Use of Calcium Antagonists in Patients with Ischemic Heart Disease and Systemic Hypertension. The American Journal of Cardiology 1997; 79:10(1):33–8.
13.Christina Gerlach Øgard, Janne Petersen, Torben Jørgensen, Thomas Almdal, Henrik Vestergaard. Serum Ionised Calcium and Cardiovascular Disease in 45-years Old Men and Women Followed for 18 Years. European Journal of Epidemiology 2006;21(2):123-7.
14.Wong ND, Sciammarella M, Arad Y, Miranda-Peats R, Polk D, Hachamovich R, Friedman J, Hayes S, Daniell A,Berman DS. Heart Disease Prevention Program. The American Journal of Cardiology 2003; 92(8):951-5.
15.Timothy S. Church, Benjamin D. Levine, Darren K. McGuire, Michael J. LaMonte, Shannon J. FitzGerald, Yiling J. Cheng, Thomas E. Kimball, Steven N. Blair, Larry W. Gibbons, Milton Z. Nichaman. Coronary artery calcium score, risk factors, and incident coronary heart disease events. Atherosclerosis 2007;190(1): 224–31.
16.Scott M Grundy. Coronary calcium as a risk factor: role in global risk assessment. J Am Coll Cardiol. 2001;37(6):1512-5.
17.Trump BF, Berezesky IK, Laiho KU, Osornio AR, Mergner WJ, Smith MW. The role of calcium in cell injury. A review. Scan Electron Microsc. 1980; 2:437-62, 492.
18.W. G. Nayler. The role of calcium in the ischemic myocardium. Am J Pathol 1981; 102(2): 262–70.
19.Lars-Fride Olsson, Rolf Odselius, Else Ribbe, Jorgen Hegbrant. Evidence of calcium phosphate depositions in stenotic arteriovenous fistulas. American Journal of Kidney Diseases 2001;38; 2:377–83.
20.Olukoga AO, Adewoye HO, Erasumus RT. Renal excretion of magnesium and calcium in diabetes mellitus. Cent Afr J Med. 1989; 35(4):378-83.
21.Joanne L. Reynolds, Alexis J. Joannides, Jeremy N. Skepper, Rosamund McNair, Leon J. Schurgers, Diane Proudfoot, Willi Jahnen-Dechent, Peter L. Weissberg and Catherine M. Shanahan. Human Vascular Smooth Muscle Cells Undergo Vesicle-Mediated Calcification in Response to Changes in Extracellular Calcium and Phosphate Concentrations: A Potential Mechanism for Accelerated Vascular Calcification in ESRD. JASN 2004;15;11:2857-67.
22.Gafter, U, Malachi, T, Barak, H, Djaldetti, M, Levi, J. Red blood cell calcium homeostasis in patients with end-stage renal disease. Journal of Laboratory and Clinical Medicine 1989; 114(3): 222-31.
23.A. J. Wing. Optimum Calcium Concentration of Dialysis Fluid for Maintenance Haemodialysis. Br Med J 1968; 19; 4(5624): 145–9.
24.Arnold J. Felsenfeld, Marc K. Drezner, Francisco Llach. Hypercalcemia and Elevated Calcitriol in a Maintenance Dialysis Patient With Tuberculosis. Arch Intern Med. 1986;146(10):1941-5.
25.Slatopolsky E, Weerts C, Lopez-Hilker S, Norwood K, Zink M, Windus D, Delmez J. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. The New England Journal of Medicine 1986;315(3):157-61.
26. Carney SL, Gillies AH. Effect of an optimum dialysis fluid calcium concentration on calcium mass transfer during maintenance hemodialysis. Clin Nephrol. 1985 Jul; 24(1):28-30.
27.A. Ross Morton, Jocelyn S. Garland, Rachel M. Holden. Reviews: Is the Calcium Correct? Measuring Serum Calcium in Dialysis Patients. Seminars in Dialysis 2010 23; 3:83–9.
28.Armando Torres, Victor Lorenzo and Eduardo Salido. Calcium Metabolism and Skeletal Problems after Transplantation. JASN 2002 ;13 (2): 551-8.
29.Armando Torres, Sagrario Garcia, Angeles G MEZ, Antonieta Gonzalez, Ysamar Barrios, Maria Teresa Concepcion, Domingo Hernandez, Jose J Garcia, Maria Dolores Checa, Victor Lorenzo and Eduardo Salido. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney International 2004;65, 705–12.
30.Linda K Massey, Helen Roman-Smith, Roger A.L Sutton. Effect of dietary oxalate and calcium on urinary oxalate and risk of formation of calcium oxalate kidney stones. Journal of the American Dietetic Association 1993; 93; 8:901–6.
30.Linda K Massey, Helen Roman-Smith, Roger A.L Sutton. Effect of dietary oxalate and calcium on urinary oxalate and risk of formation of calcium oxalate kidney stones. Journal of the American Dietetic Association 1993; 93; 8:901–6.
31.Robert A. Hiatt, Bruce Ettinger, Bette Caan, Charles P. Quesenberry Jr., Debra Duncan and John T. Citron. Randomized Controlled Trial of a Low Animal Protein, High Fiber Diet in the Prevention of Recurrent Calcium Oxalate Kidney Stones. Am.J. Epidemiol 1996;144(1):25-33.
32. Ryall RL, Fleming DE, Grover PK, Chauvet M, Dean CJ, Marshall VR. The hole truth: intracrystalline proteins and calcium oxalate kidney stones. Mol Urol. 2000 Winter; 4(4):391-402.
33.Curhan GC. Dietary calcium, dietary protein, and kidney stone formation. Mineral and Electrolyte Metabolism 1997; 23(3-6):261-4.
34.Curhan GC, Curhan SG. Dietary factors and kidney stone formation. Compr Ther. 1994; 20(9): 485-9.
35.Arie Oren, Harry Husdan, Pei-Tak Cheng, Ramesh Khanna, Andreas Pierratos, George Digenis and Dimitrios G Oreopoulo. Calcium oxalate kidney stones in patients on continuous ambulatory peritoneal dialysis. Kidney International 1984; 25:534–8.
36.Richard M. Shore, Russell W. Chesney, Richard B. Mazess, Philip G. Rose, Gerald J. Bargman. Osteopenia in juvenile diabetes. Calcified Tissue International 1981; 33; 1: 455-7.
37.Mark J Bolland, Alison Avenell, John A Baron, Andrew Grey, Graeme S MacLennan, Greg D Gamble and Ian R Reid. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ (2010); 341: c3691.
38.A. Catharine Ross, JoAnn E. Manson, Steven A. Abrams, John F. Aloia, Patsy M. Brannon,Steven K. Clinton, Ramon A. Durazo-Arvizu, J. Christopher Gallagher, Richard L. Gallo,Glenville Jones, Christopher S. Kovacs, Susan T. Mayne, Clifford J. Rosen and Sue A. Shapses. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. The Journal of Clinical Endocrinology & Metabolism 2011 ;96 :153-8.
39.Janssen HC, Samson MM, Verhaar HJ. Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation. Aging Clin Exp Res. 2010; 22(1):78-84.
40.Chen H. Hsu. Are we mismanaging calcium and phosphate metabolism in renal failure? American Journal of Kidney Diseases 1997; 4: 641–9.
41.Lindblom P, Valdemarsson S, Lindergård B, Westerdahl J, Bergenfelz A. Decreased Levels of Ionized Calcium One Year after Hemithyroidectomy: Importance of Reduced Thyroid Hormones. Horm Res 2001;55:81–7.
42.D. Harold Copp, E. C. Cameron, Barbara A. Cheney, A. George F. Davidson and K. G. Henze. Evidence for Calcitonin—A New Hormone from the Parathyroid that Lowers Blood Calcium. Endocrinology 1962; 70(5): 638-49.
43.Begic-Karup S, Wagner B, Raber W, Schneider B, Hamwi A, Waldhäusl W, Vierhapper H. Serum calcium in thyroid disease. Wien Klin Wochenschr 2001;113(1-2):65-8.
44.D. Frizel, Andrew Malleson, Vincent Marks. Plasma Levels of Ionised Calcium and Magnesium in Thyroid Disease. Lancet 1967; 289; 7504:1360–1.
45.Villar.J, Belizan J.M. Calcium During Pregnancy. Clinical nutrition 1986; 5(2): 55-62.
46.Susan Thys-Jacobs, Daniel Donovan, Anatasio Papadopoulos, Philip Sarrel, John P Bilezikian. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids 1999; 64; 6:430–5.
47.Simon Guild, Yoshiharu Itoh, John W. Kebabian, Alberto Luini and Terry Reisine. Forskolin Enhances Basal and Potassium-Evoked Hormone Release from Normal and Malignant Pituitary Tissue: The Role of Calcium. Endocrinology 1986; 118: 268–79.
48.D. E.Knight, P. F. Baker. Calcium-dependence of catecholamine release from bovine adrenal medullary cells after exposure to intense electric fields. The Journal of Membrane Biology 1982; 68; 1: 107-40.
49.E.Tremblay, M-D. Payet, N. Gallo-Payet. Effects of ACTH and angiotensin II on cytosolic calcium in cultured adrenal glomerulosa cells. Role of cAMP production in the ACTH effect. Cell Calcium 1991; 12; 1:655–73.
50.Janet C. King. Effect of Reproduction on the Bioavailability of Calcium, Zinc and Selenium. J. Nutr 2001; 131; 4: 1355S-8S.
51.N A Cross, L S Hillman, S H Allen, G F Krause, and N E Vieira. Calcium homeostasis and bone metabolism during pregnancy, lactation, and postweaning: a longitudinal study. Am J Clin Nutr 1995; 61; 3: 514-23.
52.Lorrene D Ritchie and Janet C King. Dietary calcium and pregnancy-induced hypertension: is there a relation? Am J Clin Nutr 2000; 71; 5: 1371s-4s.
53.Y. Miyake, S. Sasaki, K. Tanaka and Y. Hirota. Dairy food, calcium and vitamin D intake in pregnancy, and wheeze and eczema in infants. ERJ 2010; 35; 6: 1228-34.
54.Ann Prentice. Calcium in Pregnancy and Lactation. Annual Review of Nutrition 2000; 20: 249-72.
55.Capiod T, Shuba Y, Skryma R, Prevarskaya N. Calcium signalling and cancer cell growth. Subcell Biochem. 2007; 45:405-27.
56.Yan Cui and Thomas E. Rohan. Vitamin D, Calcium, and Breast Cancer Risk: A Review. Cancer Epidemiol Biomarkers Prev 2006; 15(8):1427-37.
57.Davis FM, Azimi I, Faville RA, Peters AA, Jalink K, Putney JW Jr, Goodhill GJ, Thompson EW, Roberts-Thomson SJ, Monteith GR. Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent. Oncogene. 2013 May 20.
58. J.C. Gallagher, D. Goldgar, Alan Moy. Total bone calcium in normal women: Effect of age and menopause status. Journal of Bone and Mineral Research(1987); Vol 2; 6:491–6.
59.AG Schuurman, PA van den Brandt, E Dorant and RA Goldbohm. Animal products, calcium and protein and prostate cancer risk in the Netherlands Cohort Study. British Journal of Cancer 1999; 80(7): 1107–13.
60.June M. Chan, Edward Giovannucci, Swen-Olof Andersson, Jonathan Yuen, Hans-Olov Adami, Alicja Wolk. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer. Cancer Causes & Control 1998; 9(6):559-66.
61.Edward Giovannucci, Eric B. Rimm, Alicja Wolk, Alberto Ascherio,Meir J. Stampfer, Graham A. Colditz, and Walter C. Willett. Calcium and Fructose Intake in Relation to Risk of Prostate Cancer. Cancer Res 1998; 58;442.
62.Alan R. Kristal, Jennifer H. Cohen, Pingping Qu, and Janet L. Stanford. Associations of Energy, Fat, Calcium, and Vitamin D with Prostate Cancer Risk. Cancer Epidemiol Biomarkers PrevAugust 2002 11; 719.
63.Edward Giovannucci, Yan Liu, Meir J. Stampfer and Walter C. Willett1. A Prospective Study of Calcium Intake and Incident and Fatal Prostate Cancer. Cancer Epidemiol Biomarkers Prev 2006; 15(2): 203-10.
64.Lukasz M. Konopka, Richard Cooper, John W. Crayton. Serotonin-induced increases in platelet cytosolic calcium concentration in depressed, schizophrenic, and substance abuse patients. Biological Psychiatry April 1996; 39(8):708–13.
65.Steven L. Dubovsky, Jennifer Christiano, Laura C. Daniell, Ronald D. Franks, James Murphy, Lawrence Adler, Neil Baker, R. Adron Harris. Increased Platelet Intracellular Calcium Concentration in Patients With Bipolar Affective Disorders. Arch Gen Psychiatry. 1989; 46(7):632-8.
66. Ichiro Kusumi, Tsukasa Koyama, Itaru Yamashita. Serotonin-induced platelet intracellular calcium mobilization in depressed patients. Psychopharmacology January 1994, 113, (3-4):322-7.
67. Stephen M Delisi, Lukasz M Konopka, Francine L O’Connor, John W Crayton. Platelet Cytosolic Calcium Responses to Serotonin in Depressed Patients and Controls: Relationship to Symptomatology and Medication. Biological Psychiatry March 1998;43(5), 1:327–34.
68.J Walleczek. Electromagnetic field effects on cells of the immune system: the role of calcium signaling. The FASEB Journal October 1992;6 (13): 3177-85.
69. argherita T Cantorna, Yan Zhu, Monica Froicu, and Anja Wittke. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr December 2004 vol. 80 no. 6 1717S-20S.
70.Stefan Feske, Jena Giltnane, Ricardo Dolmetsch, Louis M. Staudt & Anjana Rao. Gene regulation mediated by calcium signals in T lymphocytes. Nature Immunology 2001; 2:316 -24.
71.Monte M Winslow, Joel R Neilson, Gerald R Crabtree. Calcium signalling in lymphocytes. Current Opinion in Immunology June 2003;15(3): 299–307.
72.W R McKane, S Khosla, K S Egan, S P Robins, M F Burritt and B L Riggs. Role of calcium intake in modulating age-related increases in parathyroid function and bone resorption. The Journal of Clinical Endocrinology & Metabolism 1996;81(5): 1699-1703.
73.Pitkin RM. Calcium metabolism in pregnancy and the perinatal period: a review. American Journal of Obstetrics and Gynecology 1985; 151(1):99-109.
74.D A McCarron, P A Pingree, R J Rubin, S M Gaucher, M Molitch and S Krutzik. Enhanced parathyroid function in essential hypertension: a homeostatic response to a urinary calcium leak. Hypertension.1980; 2: 162-8.
75.Lawrence M. Resnick, Franco B. Müller, And John H. Laragh. Calcium-Regulating Hormones in Essential Hypertension:Relation to Plasma Renin Activity and Sodium Metabolism. Ann Intern Med. 1986; 105(5):649-54.
Article citation:-
Swaminathan.S et al. Calcium in health and disease. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1313-1323.
Copyright © 2013 Swaminathan S et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article:-
Narendra Kumar sah*1, Harnam Kaur2, Sheikh Ishaq3,K.S.Sodhi4,Jasbir Singh5,Neeru Bhaskar6 & Rajesh Pandey7
Affiliation:-
1Demonstrator, Department of Biochemistry. M.M. Medical College and Hospital, Solan, Himachal Pradesh.India.
4,5Professor, Department of Biochemistry. M.M. Institute of Medical Sciences and Research, Mullana, Ambala, Haryana-133207, India.
3Postgraduate, Department of Biochemistry. M.M. Institute of Medical Sciences and Research, Mullana, Ambala, Haryana-133207, India.
2,6,7Associate professor , Department of Biochemistry. M.M. Institute of Medical Sciences and Research, Mullana, Ambala, Haryana-133207, India.
Abstract:
One adult in ten will have diabetes by 2030; figures signify that the number of people living with diabetes is estimated to rise from 366 million in 2011 to 552 million by 2030, if no urgent action is taken. This equates to roughly three new cases every ten seconds or almost ten million per year. Microalbuminuria is present in approximately 40% of individuals after 5-10 years of type 1 DM and in 20-30% of all patients with type 2 diabetes mellitus, and is especially common in those with hypertension. Hence, the present study was undertaken to detect microalbuminuria in type II diabetes mellitus and to find out the correlation between microalbuminuria and duration of diabetes and glycemic control as well as to find out the correlation between degree of microalbuminuria and cardiovascular risk. Microalbuminuria in Type 2 diabetes mellitus was significant as the prevalence rate of microalbuminuria in the present study was 73 %. In diabetic patients with CVD, age, FPG and microalbuminuria were higher as compared with healthy controls. Thus there was also significant difference in age, levels of FPG and microalbuminuria. There was strong correlation between microalbuminuria and glycemic control (p<0.001). There was also significant correlation of microalbuminuria with the duration of diabetes without and with CVD. With the increase in duration of diabetes, there was significant progression of microalbuminuria to macroalbuminuria. This correlation was found to be higher in diabetic patients with CVD as compared with diabetics without CVD. The frequency of microalbuminuria increases with the increase in duration of diabetes. It was found in the present study that the diabetic patients having CVD had microalbuminuria ≥ 30 mg/day. Strong correlation between microalbuminuria and cardiovascular events in patients with diabetes mellitus was observed. In our study, with the increasing duration, diabetic patients with CVD had higher value of microalbuminuria.
Key Words: Diabetes mellitus, Microalbuminuria, Cardiovascular disease.
References
1.Kaur H, Bhaskar N, Ishaq S, Najeeb Q. Stem cells: Source for diabetes cell therapy.Journal of Diabetology. 2012; 3(3).
2.Powers CA. Diabetes mellitus. In: Fauci AS, Braumwald E, Kasper DL, Hauser SL, Longo BL, Jameson JL, et al editors. Harrison’s Principles of Internal Medicine. 17th edition. United States of America (NY): Mc Graw Hill Company; Inc; 2008. P. 2275- 2304.
3.Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH. Nephropathy in diabetes. Diabetes Care. 2004; 27: S79-83.
4.Donnelly R., Yeung J M, Manning G. Microalbuminuria: A common independent cardiovascular risk factor, especially but not exclusively in type 2 diabetes. J Hypertens Suppl. 2003; 21: S 7-12.
5.Lane JT. Microalbuminuria as a marker of cardiovascular and renal risk in type 2 Diabetes mellitus: a temporal perspective. Am J Physiol Renal Physiol. 2004; 286:F442-50.
6.Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Nephrol. 2007; 2:581-90.
7.Fukui M, Kitagawa Y, Nakamura N, Kadono M, Hasegawa G, Yoshikawa T. Association between urinary albumin excretion and serum Dehydroepiandrosterone sulfate concentration in male patients with type 2 diabetes. Diabetes Care. 2004; 27: 2893-7.
8.Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor, Ann. Clin. Biochem. 1969; 6: 24-5.
9.Fujita Y. Color reaction between Pyrogallol red-molybdenum (VI) complex and protein. Bunseki Kagaku. 1983; 32: E379-386.
10.Sheikh SA, Baig JA, Iqbal T, Kazmi T, Baig M, Husain SS. prevalence of microalbuminuria with relation to glycemic control in type-2 diabetic patients in Karachi. J Ayub Med Coll. 2009; 21: 83-6.
11.Maharjan BR, Bhandary S, Risal P, Sedhain A, Shakya PR, Gautam M. Microalbuminuria and macroalbuminuria in type 2 diabetes. J Nepal Health Res Counc. 2010; 8: 110-15.
12.Ninomiya T, Perkovic V, de Galan B E, Zoungas S, Pillai A, Jardine M. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009; 20: 1813- 21.
13.Rao MV, Bakris GL. Microalbuminuria- A marker of risk. US Nephrology. 2010:4: 53-55.
14.Pollak J, Sypniewsk G. Microalbuminuria and risk of cardiovascular diseases in patients with diabetes and hypertension. Biochemia Medica. 2008; 18: 25-34.
15.Stehouwer CDA, Gall MA, Twisk JWR, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Diabetes. 2002; 51: 1157-65.
16.World Medical Association decalaration of Helsinki. Ethical Principles for Medical Research involving Human subjects. World Medical Association available from; http://www.wma.net/a/policy/b3html.
Article citation:-
Sah Kumar Narendra et al. Microalbuminuria as an independent risk factor of cardiovascular disease in type 2 diabetes mellitus. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1324-1328. Available at http://www.jpbms.info.
Copyright © 2013 Sah K Narendra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article:-
1SmithaNayak, *2Vinod C Nayak, 3Shankar M Bakkannavar & 4Ravi Bagali
Affiliation:-
1Assistant Professor, Manipal Institute of Management, Manipal University, Manipal, Karnataka – 576104. India.
2*Associate Professor, Department of Forensic Medicine, Kasturba Medical College, Manipal University, Manipal , Karnataka – 576104 . India.
3Assistant Professor, Department of Forensic Medicine, Kasturba Medical College, Manipal University, Manipal , Karnataka – 576104,India.
4Student MBA 2nd Year, Manipal Institute of Management, Manipal University, Manipal, Karnataka – 576104, India.
Abstract:
Attendance rate for hospital outpatient appointments plays a pivotal role in operational efficiency of a hospital. Strategic interventions like ‘reminder systems’ prior to the scheduled appointment has proved to be an effective strategy for outpatient appointment ‘show-ups’. This study is designed with an objective to assess the effectiveness of SMS reminders as an intervention to enhance the effectiveness of hospital outpatient attendance. Method: The survey was conducted at Columbia Asia Hosiptal, Bangalore.We surveyed 60 patients who had a scheduled outpatient appointment in Department of General Medicine, Department of Obstetrics and Gynecology and the Orthopedics department, as these departments had a heavy patient flow and had higher contributions to the top line of the hospital. Results: Majority (64%) of the patients preferred to be sent an SMS reminder on the outpatient appointment schedule.37 (61%) respondents stated that the ideally, reminders could be effective only if they are sent 24-48 hours prior to the appointment schedule. 41(68%) respondents were of the opinion that a minimum of two reminders would be necessary to ensure patients show up for the appointment. 1% level of significance. It also observed that there is strong association between age and preference on mode of reminder (P=0.002).
Key Words: reminder systems; appointment show-ups; SMS reminders.
References
1.Atun AR SSR Mohan A(2005) ‘Uses and Benefits of SMS in Healthcare Delivery. Centre for Health Management. Tanaka Business School’ Imperial College London.
2.Downer, S. R., Meara, J. G. & Da Costa, A. C. (2005) 'Use of SMS text messaging to improve outpatient attendance', Med J Aust, 183 (7), 366-8.
3.Sharp D, Hamilton W. (2001) Nonattendance at general practices and outpatient clinics. BMJ, 323, 1081–2.
4.Sawyer SM, Zalan A, Bond LM. (2002) Telephone reminders improve adolescent clinic attendance: a randomized controlled trial. J Paediatr Child Health, 38(1):79-83.
5.Reekie D, Devlin H. (1998) Preventing failed appointments in general dental practice: a comparison of reminder methods. Br Dent J, 185(9):472-4.
6.Elizabeth Koshy, Josip Car and AzeemMajeed (2008) “Effectiveness of mobile-phone short message service (SMS) reminders for ophthalmology outpatient appointments: Observational study BMC Ophthalmology, 8: 9.
7.Kwok Chi Leong, Wei Seng Chen, KokWeng Leong, Ismail Mastura, Omar Mimi, Mohd Amin Sheikh, Abu Hassan Zailinawati, ChirkJenn Ng, Kai Lit Phua, and Cheong LiengTeng. (2006) The use of text messaging to improve attendance in primary care: a randomized controlled trial. Family Practice 23(6): 699-705.
8.Foley J, O'Neill M. (2009) ‘Use of mobile telephone short message service (SMS) as a reminder: the effect on patient attendance’ accessed at http://www.ncbi.nlm.nih.gov/pubmed/19254521.
9.Frankel S, Farrow A, West R. (1989) Nonattendance or non-invitation? A case controlled study of failed outpatient appointments. BMJ, 298:1343-5.
10.Cheryl D. Tierney, Hussain Yusuf, Shawn R. McMahon, Donna Rusinak, Megan A. O’ Brien, Mehran S. Massoudi, Tracy A. Lieu (2003) ‘Adoption of Reminder and Recall Messages for Immunizations by Pediatricians and Public Health Clinics’ Pediatrics.112(5); 1076-82.
11.Fahey, D. (2003) 'Reminding patients by text message: text reminders could lead to increased health inequalties', Bmj, 327 (7414), 564.
12.Lazev A, Vidrine D, Arduino R, Gritz E. (2004). “Increasing access to smoking cessation treatment in a low-income, HIV-positive population: The feasibility of using cellular telephones.” Nicotine and Tobacco Research, 6(2): 281.
13.Stone C, Palmer J, Saxby P, et al (1999) Reducing nonattendance at outpatient clinics. Journal of the Royal Society of Medicine, 92, 114–8.
14.Mary Meeker. (2012)Keliner Perkins Caufiled Byers Report. Internet Trends @ Stanford – Basis http://www.kpcb.com/insights/2012-internet-trends-update accessed on 25.03.2013.
Article citation:-
SmithaNayak,Vinod C Nayak, Shankar M Bakkannavar & Ravi Bagali. Are SMS reminders an antecedent to outpatient ‘Show-ups’?. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 July; 32(32): 1329-1332. Available at http://www.jpbms.info.
Copyright © 2013 Nayak Vinod C et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original research article:-
*1Agarwal Kishor Kumar, 2Vidya P, 3Dutt Hemant Kumar,4Saxena Alok, 5Mittal Amit & 6 Mukherjee Sukhes
Affiliation:-
1Associate Professor, Anatomy, 2Senior Resident, Anatomy, 3Assistant Professor, Pharmacology, 4Senior Resident, Anatomy, 5Statistician, Community Medicine, 6Assistant Professor, Bio Chemistry, Veer Chandra Singh Garhwali Govt. Medical Sciences and Research Institute, Srinagar (Garhwal), Uttarakhand, India.
Author contributions: - All authors contributed equally to this paper.
Abstract:
Finger print identification is an important tool for medico legal cases. They are assessed on the basis of their different patterns. They are developed during fourth month of intrauterine life and remain unchanged throughout the life. They are hereditary and show the personality of a person as well as his/ her psychological behavior. Study of frequency of finger print pattern and their repetition on all fingers of normal population & prisoners was carried out.
Aims and objectives: To detect the frequency of finger print patterns on each digit and their comparison in two different groups comprising normal hilly population and prisoners.
To access the repetition of specific pattern on individual digit of both hands.
Methods: Fifteen hundred finger prints were collected using ink technique from both groups and carefully observed.
Statistical analysis:- The difference in proportions test is used to determine significant relationship of variables. p value was marked at 95 % confidence level (p < 0.05).
Results: Whorls were most frequent on ring finger where as loops were more on little finger. Highest frequency of arches was observed on index finger and composites were unevenly distributed.
Conclusion: This study correlates the personality of an individual with different finger print pattern as well as the prevalence of most frequent pattern on a specific digit. This study may be a favorable finding to predict the finger print pattern in case of missing phalanges for medico legal investigations.
Key Words: Arch; Composite; Finger print pattern; Friction ridges; Loop, Whorl.
References
1.Katakkar STM. Encyclopedia of palm and palm reading. UBS Publishers Distributors Ltd, New Delhi. 1992, pp114-16.
2.Barnes JG. "Chapter 1: History", in The Fingerprint Sourcebook, International Association for Identification, Ed. Washington DC: National Institute of Justice. 2009.
3.Cummins H, Midlo C. Palmar and plantar epidermal ridge configurations in European Americans. Am J Phys Anthrop 1926; 9: 471-502.
4.Henry Edward R. "Classification and Uses of Finger Prints". George Rutledge an Sons Ltd. London.1900.
5.Gettings F. The Book of the Hand. Paul Hamlyn, Ltd. 1965, reprint 1968, pp115-19.
6.Hutchinson BB. Your Life in Your Hands. Neville Spearman Ltd, London.1967, pp 92-107.
7.Jaquin N. The Hand of Man. Faber & Faber Ltd. London. 1934, pp44-46
8.Cummins H, Midlo C. Finger Prints, Palms and Soles: An Introduction to Dermatoglyphics. The Blakiston Company, Philadelphia. 1943;p 9.
Article citation:-
Agarwal Kishor Kumar et al. Prevalence of digital dermatoglyphic patterns: Medico legal significance. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013, July; 32(32): 1338-1342. Available at http://www.jpbms.info.
Copyright © 2013 Agarwal Kishor Kumar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.